A new high-throughput screening-compatible gap junctional intercellular communication assay

BMC Biotechnology

Ju Yeon Lee¹  Eun Ju Choi¹  Jinu Lee¹ 

[1] College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu 406-840, Incheon, South Korea

关键词: YFP;    Iodide;    High-throughput screening;    Gap junction;   

Others  :  1228277
DOI  :  10.1186/s12896-015-0211-3

 received in 2014-12-06, accepted in 2015-10-01,  发布年份 2015

【 摘 要 】

Background

Gap junctions (GJs) are intercellular channels through which molecules smaller than 1 kDa can diffuse, and they have been suggested as drug targets. To develop chemical drugs acting on this target, a high-throughput screening (HTS) system for GJ modulators is necessary.

Results

We designed a new, high-throughput GJ intercellular communication (GJIC) assay. This assay system consisted of donor and acceptor cells from LN215 glioma cells that expressed SLC26A4 and yellow fluorescent protein-H148Q/I152L (YFP ^QL ), respectively. The fluorescence of LN215-YFP ^QLacceptor cells, when cultured alone, was not quenched by iodide. However when donor and acceptor cells, or LN215-YFP ^QLand LN215-I ⁻cells, were mixed and plated, they formed GJs. When iodide was added, it was transported into donor cells by SLC26A4, diffused through the GJs to acceptor cells, and quenched the YFP ^QLfluorescence. The quenching rate was optimal at a 2:1 mixture of donor and acceptor cells. The assay quality parameter, Z’ factor, was calculated from data collected with vehicle and carbenoxolone. For each assay, the Z’ factor increased with time. The Z’ factor of a 10-s assay was 0.72 indicating that the assay quality was high enough for use in HTS. This assay system also worked well in HOS osteosarcoma cells with a Z’ factor at 10 s of 0.70.

Conclusions

We developed a new HTS system for GJ modulators. The system had a high assay quality with a Z’ factor ≥ 0.70, was rapid and required only 10 s per well, was inexpensive in requiring no additional reagents, and was predicted to have a low rate of false-positive hits.

【 授权许可】

   
2015 Lee et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Alexander DB, Goldberg GS. Transfer of biologically important molecules between cells through gap junction channels. Curr Med Chem. 2003; 10(19):2045-58.
• [2]Willecke K, Eiberger J, Degen J, Eckardt D, Romualdi A, Guldenagel M, Deutsch U, Sohl G. Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem. 2002; 383(5):725-37.
• [3]Gerido DA, White TW. Connexin disorders of the ear, skin, and lens. Biochim Biophys Acta. 2004;1662(1–2):159–70.
• [4]Laird DW. Syndromic and non-syndromic disease-linked Cx43 mutations. FEBS Lett. 2014; 588(8):1339-48.
• [5]De Vuyst E, Boengler K, Antoons G, Sipido KR, Schulz R, Leybaert L. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol. 2011; 163(3):469-83.
• [6]Patel SJ, Milwid JM, King KR, Bohr S, Iracheta-Velle A, Li M, et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol. 2012;30(2):179–83.
• [7]Hawat G, Benderdour M, Rousseau G, Baroudi G. Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. Arch Eur J Physiol. 2010; 460(3):583-92.
• [8]Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Mineral Res. 2008; 23(11):1712-21.
• [9]Abbaci M, Barberi-Heyob M, Blondel W, Guillemin F, Didelon J. Advantages and limitations of commonly used methods to assay the molecular permeability of gap junctional intercellular communication. BioTech. 2008; 45(1):33-52.
• [10]Kanno Y, Loewenstein WR. Intercellular diffusion. Science. 1964; 143(3609):959-60.
• [11]El Fouly MH, Trosko JE, Chang CC. Scrape-loading and dye transfer. A rapid and simple technique to study gap junctional intercellular communication. Exp Cell Res. 1987; 168(2):422-30.
• [12]Raptis LH, Brownell HL, Firth KL, Mackenzie LW. A novel technique for the study of intercellular, junctional communication: electroporation of adherent cells on a partly conductive slide. DNA Cell Biol. 1994; 13(9):963-75.
• [13]Wade MH, Trosko JE, Schindler M. A fluorescence photobleaching assay of gap junction-mediated communication between human cells. Science. 1986; 232(4749):525-8.
• [14]Galietta LJ, Haggie PM, Verkman AS. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett. 2001; 499(3):220-4.
• [15]Tani E, Nishiura M, Higashi N. Freeze-fracture studies of gap junctions of normal and neoplastic astrocytes. Acta Neuropathol. 1973; 26(2):127-38.
• [16]Davidson JS, Baumgarten IM, Harley EH. Reversible inhibition of intercellular junctional communication by glycyrrhetinic acid. Biochemical and biophysical research communications. 1986; 134(1):29-36.
• [17]Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for Use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999; 4(2):67-73.
• [18]Li Z, Yan Y, Powers EA, Ying X, Janjua K, Garyantes T, et al. Identification of gap junction blockers using automated fluorescence microscopy imaging. J Biomol Screen. 2003;8(5):489–99.
• [19]Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem. 1993; 268(29):21493-6.
• [20]Haq N, Grose D, Ward E, Chiu O, Tigue N, Dowell SJ, et al. A high-throughput assay for connexin 43 (Cx43, GJA1) gap junctions using codon-optimized aequorin. Assay Drug Dev Technol. 2013;11(2):93–100.
• [21]Penuela S, Gehi R, Laird DW. The biochemistry and function of pannexin channels. Biochim Biophys Acta. 2013; 1828(1):15-22.
• [22]Sahu G, Sukumaran S, Bera AK. Pannexins form gap junctions with electrophysiological and pharmacological properties distinct from connexins. Sci Reports. 2014; 4:4955.
• [23]Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, et al. Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science. 2002;298(5592):425–9.
• [24]Olbina G, Eckhart W. Mutations in the second extracellular region of connexin 43 prevent localization to the plasma membrane, but do not affect its ability to suppress cell growth. Mol Cancer Res. 2003; 1(9):690-700.